Economic costs, health-related quality of life outcomes and cost-utility of a physical and psychological group intervention targeted at older adults with neurogenic claudication

Cost Effectiveness and Resource Allocation

Research

Maredza Mandy¹  Sarah E. Lamb²  Petrou Stavros³  Susan J. Dutton⁴  Ioana R. Marian⁴  Williamson Esther⁵  Khan Kamran⁶ 

[1] Division of Health Sciences, Warwick Medical School, The University of Warwick, Coventry, UK;Exeter Medical School, University of Exeter, Devon, UK;Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK;Oxford Clinical Trials Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK;Oxford Clinical Trials Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK;Exeter Medical School, University of Exeter, Devon, UK;Warwick Clinical Trials Unit, University of Warwick, Warwick, UK;

关键词: Economic costs;    Health-related quality of life;    Cost-effectiveness;    Spinal stenosis;    Neurogenic claudication;    Rehabilitation;    Exercise;    Psychosocial;   

DOI  :  10.1186/s12962-022-00410-y

 received in 2022-09-06, accepted in 2022-12-16,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundEmerging evidence suggests that structured and progressive exercise underpinned by a cognitive behavioural approach can improve functional outcomes in patients with neurogenic claudication (NC). However, evidence surrounding its economic benefits is lacking.ObjectivesTo estimate the economic costs, health-related quality of life outcomes and cost-effectiveness of a physical and psychological group intervention (BOOST programme) versus best practice advice (BPA) in older adults with NC.MethodsAn economic evaluation was conducted based on data from a pragmatic, multicentre, superiority, randomised controlled trial. The base-case economic evaluation took the form of an intention-to-treat analysis conducted from a UK National Health Service (NHS) and personal social services (PSS) perspective and separately from a societal perspective. Costs (£ 2018–2019 prices) were collected prospectively over a 12 month follow-up period. A bivariate regression of costs and quality-adjusted life-years (QALYs), with multiple imputation of missing data, was conducted to estimate the incremental cost per QALY gained and the incremental net monetary benefit (INMB) of the BOOST programme in comparison to BPA. Sensitivity and pre-specified subgroup analyses explored uncertainty and heterogeneity in cost-effectiveness estimates.ResultsParticipants (N = 435) were randomised to the BOOST programme (n = 292) or BPA (n = 143). Mean (standard error [SE]) NHS and PSS costs over 12 months were £1,974 (£118) in the BOOST arm versus £1,827 (£169) in the BPA arm (p = 0.474). Mean (SE) QALY estimates were 0.620 (0.009) versus 0.599 (0.006), respectively (p = 0.093). The probability that the BOOST programme is cost-effective ranged between 67 and 83% (NHS and PSS perspective) and 79–89% (societal perspective) at cost-effectiveness thresholds between £15,000 and £30,000 per QALY gained. INMBs ranged between £145 and £464 at similar cost-effectiveness thresholds. The cost-effectiveness results remained robust to sensitivity analyses.ConclusionsThe BOOST programme resulted in modest QALY gains over the 12 month follow-up period. Future studies with longer intervention and follow-up periods are needed to address uncertainty around the health-related quality of life impacts and cost-effectiveness of such programmes.Trial registration This study has been registered in the International Standard Randomised Controlled Trial Number registry, reference number ISRCTN12698674. Registered on 10 November 2015.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 11

12936_2023_4464_Article_IEq7.gif

Fig. 7